DE69312528T2 - Verfahren zur Herstellung von Fibrinogen-Rezeptor-Antagonisten - Google Patents

Verfahren zur Herstellung von Fibrinogen-Rezeptor-Antagonisten

Info

Publication number
DE69312528T2
DE69312528T2 DE69312528T DE69312528T DE69312528T2 DE 69312528 T2 DE69312528 T2 DE 69312528T2 DE 69312528 T DE69312528 T DE 69312528T DE 69312528 T DE69312528 T DE 69312528T DE 69312528 T2 DE69312528 T2 DE 69312528T2
Authority
DE
Germany
Prior art keywords
preparation
receptor antagonists
fibrinogen receptor
fibrinogen
antagonists
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69312528T
Other languages
English (en)
Other versions
DE69312528D1 (de
Inventor
John Y L Chung
David L Hughes
Dalian Zhao
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Iroko Cardio LLC
Original Assignee
Merck and Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck and Co Inc filed Critical Merck and Co Inc
Publication of DE69312528D1 publication Critical patent/DE69312528D1/de
Application granted granted Critical
Publication of DE69312528T2 publication Critical patent/DE69312528T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/28Radicals substituted by singly-bound oxygen or sulphur atoms
    • C07D213/30Oxygen atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/01Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms
    • C07C311/02Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C311/03Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atoms of the sulfonamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C311/06Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atoms of the sulfonamide groups bound to hydrogen atoms or to acyclic carbon atoms to acyclic carbon atoms of hydrocarbon radicals substituted by carboxyl groups
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/20Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
    • C07D211/22Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms by oxygen atoms

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
DE69312528T 1992-02-28 1993-02-20 Verfahren zur Herstellung von Fibrinogen-Rezeptor-Antagonisten Expired - Lifetime DE69312528T2 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/843,658 US5206373A (en) 1992-02-28 1992-02-28 Process for preparing fibrinogen receptor antagonists

Publications (2)

Publication Number Publication Date
DE69312528D1 DE69312528D1 (de) 1997-09-04
DE69312528T2 true DE69312528T2 (de) 1998-02-19

Family

ID=25290632

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69312528T Expired - Lifetime DE69312528T2 (de) 1992-02-28 1993-02-20 Verfahren zur Herstellung von Fibrinogen-Rezeptor-Antagonisten

Country Status (25)

Country Link
US (1) US5206373A (de)
EP (2) EP0738714B1 (de)
JP (1) JP2674679B2 (de)
KR (1) KR100187779B1 (de)
CN (1) CN1050832C (de)
AR (1) AR247878A1 (de)
AT (1) ATE156118T1 (de)
AU (2) AU3732293A (de)
CA (1) CA2090509C (de)
CZ (1) CZ283485B6 (de)
DE (1) DE69312528T2 (de)
DK (1) DK0558139T3 (de)
ES (2) ES2105069T3 (de)
FI (1) FI106023B (de)
GR (2) GR3024965T3 (de)
HU (2) HU226957B1 (de)
LV (1) LV12824B (de)
MX (1) MX9301045A (de)
NZ (1) NZ249751A (de)
RO (1) RO116016B1 (de)
RU (2) RU2114105C1 (de)
SK (1) SK281250B6 (de)
TW (1) TW229206B (de)
WO (1) WO1993016995A1 (de)
YU (1) YU49077B (de)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1264813B1 (it) * 1993-07-28 1996-10-10 Oxon Italia Spa Procedimento per la preparazione di alcansolfonammidi
US5780480A (en) * 1996-02-28 1998-07-14 Merck & Co., Inc. Fibrinogen receptor antagonists
US5980951A (en) * 1996-04-10 1999-11-09 Merck & Co., Inc. Oral coated active drugs
CA2259487A1 (en) 1996-07-01 1998-01-08 Margaret Mary Faul Hypoglycemic and hypolipidemic compounds
GB9812088D0 (en) * 1998-06-05 1998-08-05 Celltech Therapeutics Ltd Chemical compounds
CN1330636C (zh) * 2005-09-26 2007-08-08 鲁南制药集团股份有限公司 盐酸替罗非班中间体的合成方法
CN102452975A (zh) * 2010-11-01 2012-05-16 天津康鸿医药科技发展有限公司 盐酸替罗非班中间体合成方法
CN104447509B (zh) * 2013-09-18 2016-08-24 嘉实(湖南)医药科技有限公司 一种盐酸替罗非班的制备工艺
CN108440393A (zh) * 2018-03-20 2018-08-24 成都倍特药业有限公司 替罗非班物料杂质、杂质制备及物料中杂质检测方法
CN109608387A (zh) * 2019-01-02 2019-04-12 海门慧聚药业有限公司 盐酸替罗非班的制备
CN111100066B (zh) * 2019-11-29 2021-07-30 石药集团恩必普药业有限公司 一种盐酸替罗非班中间体及盐酸替罗非班的制备方法
CN112816282B (zh) * 2020-12-29 2022-04-12 江苏慧聚药业股份有限公司 一种盐酸替罗非班的有关物质及其制备和检测方法
CN115181058A (zh) * 2021-04-01 2022-10-14 武汉武药科技有限公司 组合物及其质量控制方法
CN114315697A (zh) * 2021-12-20 2022-04-12 河北国龙制药有限公司 一种盐酸替罗非班的制备方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB756713A (en) * 1953-07-06 1956-09-05 Ciba Ltd Substituted piperidines and process of making them
GB772516A (en) * 1953-12-22 1957-04-17 Ciba Ltd Piperidines and process of making same
GB939019A (en) * 1959-01-19 1963-10-09 Aspro Nicholas Ltd Diphenyl methane derivatives and methods for the preparation thereof
IT1062206B (it) * 1974-02-01 1983-09-20 Rotta Research Lab S P A A S Derivati della tirosina attivi sulla muscolatura liscia
DE2809377A1 (de) * 1978-03-04 1979-09-13 Boehringer Mannheim Gmbh Phenoxyalkylcarbonsaeure-derivate, verfahren zu deren herstellung sowie diese verbindungen enthaltende arzneimittel
US5084466A (en) * 1989-01-31 1992-01-28 Hoffmann-La Roche Inc. Novel carboxamide pyridine compounds which have useful pharmaceutical utility
CA2008116C (en) * 1989-02-23 2001-11-20 Thomas Weller Glycine derivatives
IL99537A (en) * 1990-09-27 1995-11-27 Merck & Co Inc Fibrinogen receptor antagonists and pharmaceutical preparations containing them
NZ239846A (en) * 1990-09-27 1994-11-25 Merck & Co Inc Sulphonamide derivatives and pharmaceutical compositions thereof

Also Published As

Publication number Publication date
EP0738714A2 (de) 1996-10-23
SK102294A3 (en) 1995-04-12
EP0558139B1 (de) 1997-07-30
ES2105069T3 (es) 1997-10-16
CA2090509C (en) 1997-02-25
ATE156118T1 (de) 1997-08-15
KR100187779B1 (ko) 1999-06-01
LV12824B (en) 2002-09-20
HU226957B1 (en) 2010-03-29
TW229206B (de) 1994-09-01
JP2674679B2 (ja) 1997-11-12
HUT70537A (en) 1995-10-30
EP0738714A3 (de) 1996-11-20
FI943933A (fi) 1994-10-04
JPH069557A (ja) 1994-01-18
US5206373A (en) 1993-04-27
GR3024965T3 (en) 1998-01-30
HU9402467D0 (en) 1994-10-28
AU3383693A (en) 1993-09-02
DE69312528D1 (de) 1997-09-04
YU13193A (sh) 1997-07-31
CZ283485B6 (cs) 1998-04-15
EP0738714B1 (de) 2001-05-02
FI106023B (fi) 2000-11-15
LV12824A (en) 2002-05-20
CZ203394A3 (en) 1995-10-18
AR247878A1 (es) 1995-04-28
RU2097377C1 (ru) 1997-11-27
SK281250B6 (sk) 2001-01-18
YU49077B (sh) 2003-08-29
RU94040166A (ru) 1996-07-10
ES2156255T3 (es) 2001-06-16
DK0558139T3 (da) 1997-09-01
FI943933A0 (fi) 1994-08-26
AU657199B2 (en) 1995-03-02
RO116016B1 (ro) 2000-09-29
HU9600658D0 (en) 1996-05-28
EP0558139A1 (de) 1993-09-01
CN1050832C (zh) 2000-03-29
WO1993016995A1 (en) 1993-09-02
CN1076441A (zh) 1993-09-22
HU217959B (hu) 2000-05-28
AU3732293A (en) 1993-09-13
KR950700252A (ko) 1995-01-16
MX9301045A (es) 1993-09-01
GR3035827T3 (en) 2001-08-31
NZ249751A (en) 1996-06-25
CA2090509A1 (en) 1993-08-29
RU2114105C1 (ru) 1998-06-27

Similar Documents

Publication Publication Date Title
DE69216903D1 (de) Verfahren zur Herstellung von Isoparaffinen
DE69312528T2 (de) Verfahren zur Herstellung von Fibrinogen-Rezeptor-Antagonisten
DE59308715D1 (de) Verfahren zur Herstellung von Dimethylchlorsilan
DE59303220D1 (de) Verfahren zur Herstellung von 1-Fluorcyclopropyl-methyl-keton
DE59305389D1 (de) Verfahren zur Herstellung von alpha-Fluor -beta-dicarbonylverbindungen
DE59205077D1 (de) Verfahren zur Herstellung von Chlorfluornitrobenzolen
DE69314899T2 (de) Verfahren zur Herstellung von Polyaminoborazinen
DE69315297D1 (de) Verfahren zur Herstellung von Omega-Alkenylchlorsilanen
DE69311213T2 (de) Verfahren zur Herstellung von 1-Aza-2-silacyclopentan-Verbindungen
DE59309922D1 (de) Verfahren zur Herstellung von substituierten 2,3-Difluorpyridinen
DE69332766T2 (de) Verfahren zur Herstellung von Sulfonaten
DE69325079T2 (de) Verfahren zur Herstellung von Triorganochlorsilane
DE69303057D1 (de) Verfahren zur Herstellung von 3-Cyano-6-hydroxypyridin
DE59205946D1 (de) Verfahren zur Herstellung von 2-Aminomethylpiperidin
DE59205092D1 (de) Verfahren zur Herstellung von 2-Nitro-5-fluor- bzw. -5-chlor-phenol
DE69315317T2 (de) Verfahren zur Herstellung von beta-Cyanoalkylsilanen
DE69321661T2 (de) Verfahren zur Herstellung von Triorganomonohalogensilan
DE69318765T2 (de) Verfahren zur Herstellung von Hydridoorganooxysilanen
DE59306959D1 (de) Verfahren zur Herstellung von Difluor- und Chlorfluorbenzodioxolen
DE69305279T2 (de) Verfahren zur Herstellung von Dimethyltetralin
DE69308193D1 (de) Verfahren zur Herstellung von Alpha-L-Aspartyl-L-Phenylalanin
DE59304663D1 (de) Verfahren zur Herstellung von 4-Hydroxymethyltetrahydropyran
DE69322893D1 (de) Verfahren zur Herstellung von Epsilon-poly-L-Lysin
DE69315979D1 (de) Verfahren zur Herstellung von 1-Phenoxy-2-aminopropan
DE59310105D1 (de) Verfahren zur Herstellung von 2-Amino-5-methyl-pyridin

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8327 Change in the person/name/address of the patent owner

Owner name: IROKO CARDIO, LLC, PHILADELPHIA, PA., US